Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

Howard Trachtman, Suzanne Vento, Debbie Gipson, Larysa Wickman, Jennifer Gassman, Melanie Joy, Virginia Savin, Michael Somers, Maury Pinsk, Tom Greene, Howard Trachtman, Suzanne Vento, Debbie Gipson, Larysa Wickman, Jennifer Gassman, Melanie Joy, Virginia Savin, Michael Somers, Maury Pinsk, Tom Greene

Abstract

Background: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies. Recent basic science advances have led to development of alternative treatments that specifically target aberrant pathways of fibrosis which are relevant to disease progression in FSGS. There is a need for a flexible Phase II study design which will test such novel antifibrotic strategies in order to identify agents suitable for phase III testing.

Methods/design: The Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) project is a multicenter Phase I/II RCT designed to investigate the potential efficacy of novel therapies for resistant FSGS. Adalimumab and galactose will be evaluated against conservative therapy consisting of the combination of lisinopril, losartan and atorvastatin. The sample size is defined to assure that if one of the treatments has a superior response rate compared to that of the other treatments, it will be selected with high probability for further evaluation. Comparison of primary and secondary endpoints in each study arm will enable a choice to be made of which treatments are worthy of further study in future Phase III RCT.

Discussion: This report highlights the key features of the FONT II RCT including the two-step outcome analysis that will expedite achievement of the study objectives. The proposed phase II study design will help to identify promising agents for further testing while excluding ineffective agents. This staged approach can help to prevent large expenditures on unworthy therapeutic agents in the management of serious but rare kidney diseases.

Trial registration: ClinicalTrials.gov NCT00814255.

Figures

Figure 1
Figure 1
FONT II Trial Design.

References

    1. Burgess E. Management of focal segmental glomerulosclerosis: Evidence-based recommendations. Kidney Int. 1999;55:S26–S32. doi: 10.1046/j.1523-1755.1999.07004.x.
    1. Benchimol C. Focal segmental glomerulosclerosis: pathogenesis and treatment. Curr Opin Pediatr. 2003;15:171–80. doi: 10.1097/00008480-200304000-00006.
    1. Jafar TH, Stark PC, Schmid CH. for the AIPRD Study Group et al.Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40. doi: 10.1046/j.1523-1755.2001.0600031131.x.
    1. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–74.
    1. Lama G, Luongo I, Piscitelli A, Salsano ME. Enalapril: Antiproteinuric effect in children with nephrotic syndrome. Clin Nephrol. 2000;53:432–6.
    1. McLaughlin K, Jardine AG. Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease? Nephrol Dial Transplant. 1999;14:25–8. doi: 10.1093/ndt/14.1.25.
    1. Milliner DS, Morgenstern BZ. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 1991;5:587–90. doi: 10.1007/BF00856646.
    1. Navis G, de Zeeuw D, de John PE. ACE-inhibitors: Panacea for progressive renal disease? Lancet. 1997;349:1852–3. doi: 10.1016/S0140-6736(97)22026-X.
    1. Proesmans W, Van Wambeke I, Van Dyck M. Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Pediatr Nephrol. 1996;10:587–9. doi: 10.1007/s004670050166.
    1. Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: A retrospective study in a single clinic. Clin Nephrol. 2001;56:89–95.
    1. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25. doi: 10.1053/ajkd.2001.25176.
    1. Woo KT, Lau YK, Wong KS, Chiang GS. ACEi/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000;58:2485–91. doi: 10.1046/j.1523-1755.2000.00432.x.
    1. Fried L, Orchard TJ, Kasiske BL. for the Lipids and renal Disease Progression Meta-Analysis Study Group. effect of lipoid reduction on progression of renal disease: A meta-analysis. Kidney Int. 2001;59:260–9. doi: 10.1046/j.1523-1755.2001.00487.x.
    1. Schieppati A, Remuzzi G. the future of renoprotection: frustration and promises. Kidney Int. 2003;63:1947–55. doi: 10.1046/j.1523-1755.2003.00340.x.
    1. Brenner BM. Retarding the progression of renal disease. Kidney Int. 2003;63:370–8. doi: 10.1046/j.1523-1755.2003.t01-2-00052.x.
    1. Zoja C, Corna D, Camozzi D, Cattaneo D. et al.How to fully protect the kidney in a more severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13:2898–908. doi: 10.1097/.
    1. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman S, Rovin BH. Renoprotection: One or many therapies? Kidney Int. 2001;59:1211–1226. doi: 10.1046/j.1523-1755.2001.0590041211.x.
    1. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433–8.
    1. Gertzberg N, Neumann P, Rizzo V, Johnson A. NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-α. Am J Physiology. 2004;286:L37–L48.
    1. Wright SC, Zheng H, Zhong J, Torti FM, Larrick JW. Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. J Cell Biochem. 1993;53:222–33. doi: 10.1002/jcb.240530307.
    1. Gaur U, Aggerwal BB. Regulation of proliferation, survival, and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66:1403–8. doi: 10.1016/S0006-2952(03)00490-8.
    1. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, Gonzalez E, Egido J. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp. 1995;24:53–77.
    1. Cattran D, Neogi T, McCarthy ET, Savin VJ, Sharma R. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol. 2003;4:448–53. doi: 10.1097/01.ASN.0000046960.57614.17.
    1. Savin VJ, Sharma R, Sharma M. et al.Circulating factor increasing glomerular permeability in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334:878–883. doi: 10.1056/NEJM199604043341402.
    1. Savin VJ, McCarthy ET, Sharma R, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Translational Research. 2008;151:288–292. doi: 10.1016/j.trsl.2008.04.001.
    1. DeSmet E, Rioux JP, Ammann H, Deziel C, Querin S. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant. 2009;24:2938–40. doi: 10.1093/ndt/gfp278.
    1. Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. pp. 487–491.
    1. Cattran DC, Appel GB, Hebert LA. et al.A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220–6. doi: 10.1046/j.1523-1755.1999.00778.x.
    1. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009;4(1):39–47. doi: 10.2215/CJN.02310508. Epub 2008 Dec 10.
    1. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of adalimumab in focal segmental glomerulosclerosis: II. Report of the FONT (novel therapies for resistant FSGS) study group. Am J Kid Dis. 2010;55:50–60. doi: 10.1053/j.ajkd.2009.08.019.
    1. Peyser A, MacHardy N, Tarapore F, MacHardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol. 2010;11:2. doi: 10.1186/1471-2369-11-2.
    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.
    1. Caridi G, Bertelli R, Carrea A. et al.Prevalence, genetics and clinical features of patients carrying podocin mutations in steroid resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001;12:2742–6.
    1. Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Sem Nephrol. 2003;23:141–146. doi: 10.1053/snep.2003.50014.
    1. Ruf RG, Lichtenberger A, Karle SM. et al.Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephritic syndrome. J Am Soc Nephrol. 2004;15:722–32. doi: 10.1097/01.ASN.0000113552.59155.72.
    1. Caridi G, Bertelli R, DiDuca M. et al.Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003;14:1278–86. doi: 10.1097/01.ASN.0000060578.79050.E0.
    1. Liu P. In: Handbook of Statistics in Clinical Oncology. John Crowley, editor. Chapter 6. Marcel Dekker; 2001. Phase II Selection Designs; pp. 119–127.
    1. Simon R, Wittes R, Ellenberg. Randomized phase II clinical trials. Cancer Treatment Rep. 1985;69:1375–81.
    1. Buyse M. Randomized designs for early trials of new cancer treatments - An overview. Drug Information Journal. 2000;34:387–396.
    1. Korbet SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:219–28. doi: 10.1053/snep.2003.50020.
    1. Franceschini N, Hogan SL, Falk RJ. Primum non nocere: Should adults with idiopathic FSGS receive steroids? Semin Nephrol. 2003;23:229–33. doi: 10.1053/snep.2003.50021.
    1. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kid Dis. 1998;32:72–9. doi: 10.1053/ajkd.1998.v32.pm9669427.
    1. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol. 1992;2(12 Suppl):S258–S263.
    1. Senggutuvan P, Cameron JS, Hartley RB. et al.Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol. 1990;4:21–8. doi: 10.1007/BF00858431.
    1. Huang K, Ferris ME, Andreoni KA, Gipson DS. The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:1082–1090. doi: 10.1053/j.ajkd.2004.03.017.
    1. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int. 2002;62:2301–10. doi: 10.1046/j.1523-1755.2002.00674.x.
    1. Ponticelli C, Passerini P. Other immunosuppressive agents for focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:242–8. doi: 10.1053/snep.2003.50023.
    1. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–80. doi: 10.1001/archinte.168.19.2070.
    1. Phillips PJ, Twigg SM. Oral hypoglycaemics - a review of the evidence. Aust Fam Physician. 2010;39(9):651–3.
    1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin. 2003;53:27–43. doi: 10.3322/canjclin.53.1.27.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner